Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.46 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GMNN | O75496 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.42 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | APEX1 | P27695 | 1/20 | 0.42 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.42 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.42 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.42 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5820404 | 0.84 | GABRA1 (0.48) | KDM4EALDH1A1MAPTLMNACYP1A2 | |
| SCHEMBL27524296 | 0.81 | KDM4E (0.43) | KDM4EPOLBALDH1A1TSHRMAPT | |
| SCHEMBL8883732 | 0.81 | MAPT (0.47) | KDM4EPOLBALDH1A1TSHRMAPT | |
| SCHEMBL10328703 | 0.81 | KDM4E (0.43) | KDM4EPOLBALDH1A1TSHRMAPT | |
| SCHEMBL27837816 | 0.81 | OPRK1 (0.47) | KDM4EPOLBALDH1A1TSHRMAPT | |
| SCHEMBL5820179 | 0.81 | NPSR1 (0.42) | KDM4EALDH1A1TSHRCYP3A4GABRA1 | |
| SCHEMBL20918389 | 0.80 | ALDH1A1 (0.39) | KDM4EALDH1A1MAPTLMNACYP1A2 | |
| SCHEMBL19243352 | 0.79 | NPSR1 (0.41) | KDM4EPOLBALDH1A1TSHRMAPT | |
| SCHEMBL17512626 | 0.79 | NQO2 (0.44) | KDM4EPOLBALDH1A1TSHRMAPT | |
| SCHEMBL15991274 | 0.79 | KDM4E (0.42) | KDM4EPOLBALDH1A1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12606544-B2 | JAK1 selective kinase inhibitor | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2026-04-21 | — | — | US | disclosed |
| EP-3956322-B1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL JIANGSU PHARMACEUTICAL CO LTD (CN) | 2025-05-14 | — | — | EP | disclosed |
| CN-113710664-B | JAK1 selective kinase inhibitors | 迪哲(江苏)医药股份有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20220220096-A1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| US-20220220096-A1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-07-14 | — | — | US | disclosed |
| EP-3956322-A1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2022-02-23 | — | — | EP | disclosed |
| CN-113710664-A | JAK1 selective kinase inhibitors | 迪哲(江苏)医药股份有限公司 | 2021-11-26 | — | — | CN | disclosed |
| WO-2020211839-A1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2020-10-22 | — | — | WO | disclosed |
| WO-2020211839-A1 | JAK1 SELECTIVE KINASE INHIBITOR | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2020-10-22 | — | — | WO | disclosed |
| CN-1328261-C | Uracil compounds and their use | SUMITOMO CHEMICAL CO (JP) | 2007-07-25 | — | — | CN | disclosed |
| CN-1636981-A | Uracil compounds and their use | SUMITOMO CHEMICAL CO (JP) | 2005-07-13 | — | — | CN | disclosed |
| CN-1204137-C | Uracil compound and application thereof | SUMITOMO CHEMICAL CO (JP) | 2005-06-01 | — | — | CN | disclosed |
| CN-1316426-A | Uracil compound and application thereof | SUMITOMO CHEMICAL CO (JP) | 2001-10-10 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220220096-A1 | JAK1 SELECTIVE KINASE INHIBITOR | JAK1, JAK2, JAK3 | KDM4E 2137/4885POLB 2411/4885ALDH1A1 1434/4885 |
| US-12606544-B2 | JAK1 selective kinase inhibitor | JAK1, JAK2, JAK3 | KDM4E 2342/4885POLB 2684/4885ALDH1A1 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.